Related Experiment Video
Updated: Mar 7, 2026
09:40
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
3.3K
FoxM1-mediated RFC5 expression promotes temozolomide resistance
Wan-Xin Peng1, Xiu Han1, Chun-Li Zhang1
1School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, 212013, China.
Cell Biology and Toxicology
|February 11, 2017
Summary
Forkhead box M1 (FoxM1) drives temozolomide (TMZ) resistance in glioma by activating DNA repair gene RFC5, independent of MGMT. Inhibiting FoxM1 with thiostrepton may overcome this resistance.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Genetics
Background:
- Methylguanine-DNA-methyltransferase (MGMT) is crucial for temozolomide (TMZ) resistance in glioma, but many MGMT-inactivated gliomas remain resistant.
- The mechanisms underlying this persistent TMZ resistance are not fully understood.
Purpose of the Study:
- To investigate the role of forkhead box M1 (FoxM1) in mediating TMZ resistance in glioma, independent of MGMT.
- To explore the potential of targeting the FoxM1 pathway for overcoming TMZ resistance.
Main Methods:
- Correlation analysis of FoxM1 and RFC5 expression in human glioma cells.
- Investigation of FoxM1's transcriptional activity on the RFC5 promoter.
- Assessment of the effects of FoxM1 and RFC5 knockdown on TMZ sensitivity.
- Evaluation of thiostrepton, a FoxM1 inhibitor, in combination with TMZ in glioma cells.
Main Results:
- FoxM1 expression positively correlates with RFC5 expression in human glioma cells.
- FoxM1 directly activates RFC5 expression via its promoter.
- Knockdown of FoxM1 or RFC5 partially restores sensitivity to TMZ.
- The combination of thiostrepton and TMZ significantly inhibits glioma cell proliferation and induces apoptosis.
Conclusions:
- The FoxM1-RFC5 axis represents a novel mechanism contributing to TMZ resistance in glioma, independent of MGMT.
- Targeting FoxM1 with thiostrepton offers a potential therapeutic strategy to overcome TMZ resistance in glioma.
More Related Videos
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
22.1K
10:49A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers
Published on: September 26, 2019
6.0K
Related Concept Videos
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
03:03mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K
01:06Induced Pluripotent Stem Cells
5.7K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
5.7K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
60
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
02:23Abnormal Proliferation
5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
02:07Tumor Progression
7.7K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.7K